Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Inspection included drug device combinations covering our recent filing in nasal sprays domain
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Company to launch product after the expiry of semaglutide patent in India
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Vanda strongly disputes the FDA’s reasoning
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Subscribe To Our Newsletter & Stay Updated